AP NEWS

Erectile Dysfunction Pipeline Review, H2 2018 - Therapeutic Assessment of 22 Companies & Drug Profile Activity - ResearchAndMarkets.com

September 25, 2018

DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Erectile Dysfunction - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Erectile Dysfunction - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 2, 6, 6, 1, 12, 2 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Report Coverage Erectile Dysfunction - Overview Erectile Dysfunction - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Erectile Dysfunction - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Erectile Dysfunction - Companies Involved in Therapeutics Development Apricus Biosciences Inc Aquestive Therapeutics Inc Astellas Pharma Inc Biolab Farmaceutica Ltda Biopharm GmbH Biozeus Pharmaceutical SA Can-Fite BioPharma Ltd Fabre-Kramer Pharmaceuticals Inc Futura Medical Plc Humanetics Corp IntelGenx Corp Ion Channel Innovations LLC Karessa Pharma Holding AB Mezzion Pharma Co Ltd Mitsubishi Tanabe Pharma Corp N4 Pharma Plc NAL Pharmaceuticals Ltd Pharmicell Co Ltd SK Chemicals Co Ltd Suda Pharmaceuticals Ltd XuanZhu Pharma Co Ltd Yangtze River Pharmaceutical Group For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/n494rp/erectile?w=4.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180925006199/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Sexual and Reproductive Health Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS OTHER HEALTH CONSUMER MEN

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/25/2018 05:15 PM/DISC: 09/25/2018 05:15 PM

http://www.businesswire.com/news/home/20180925006199/en

AP RADIO
Update hourly